Series B Health & Wellness Funders

Collaborative Fund is a leading venture capital firm established in 2010 that backs entrepreneurs pushing the world forward. The fund operates at the intersection of for-profit and for-good, supporting companies across five main sectors: Consumer, AI, Money, Health, and Energy. Their portfolio includes notable companies like Lyft, Reddit, Sweetgreen, Impossible Foods, and Commonwealth Fusion Systems. The firm focuses on identifying and supporting businesses that combine financial returns with positive social and environmental impact, investing in category-defining brands and transformative technologies that address major challenges facing society.

Lightrock is a global impact investment platform that backs technology-enabled growth companies across People, Planet, and Productivity themes. Established as an independent platform in 2021 and backed by LGT and the Princely House of Liechtenstein, it sits between growth equity and impact PE for founders scaling proven solutions. Private-market strategies include Growth Solutions, a Climate Impact Fund that closed at €860M, Latin America growth funds, and energy-access strategies such as Accelerate7 for Sub-Saharan Africa, South Asia, and Southeast Asia. Public materials cite on the order of $5.8B assets under advice at the platform level, 90+ private equity portfolio companies, and teams across four continents. Climate Impact tickets have been described in the roughly €10M to €40M range for Europe and North America net-zero companies. Lightrock typically prefers meaningful minority stakes and board participation, pairing commercial growth support with impact and ESG monitoring. The platform also has public-markets capabilities, but the directory-relevant story for most founders is private growth capital with an explicit impact frame. If you are past early product risk and need a global growth partner that still takes People, Planet, and Productivity seriously, Lightrock is a major node.

T1D Fund is the world's first scaled venture fund dedicated exclusively to type 1 diabetes, operating as an impact investment fund that supports promising companies through equity investments and expertise. They focus specifically on accelerating treatments, prevention, and cures for the approximately 9 million people living with T1D globally. The fund operates as a powerful platform for collaboration, using catalytic capital and expertise to de-risk investments and create a flywheel effect that attracts other investors to the T1D space. As a wholly owned, not-for-profit independently run subsidiary of Breakthrough T1D, they leverage their intellectual capital and expert network to offer comprehensive support to portfolio companies, steering them through regulatory, clinical, and commercial milestones. With over $200 million in assets under management and 25+ active portfolio companies, T1D Fund creates significant impact in the diabetes ecosystem by reinvesting 100% of returns to propel continuous progress. Their unique position as subject matter experts combined with access to Breakthrough T1D's extensive network of research, clinical, and medical expertise enables them to transform the landscape of T1D investment and accelerate the development of life-changing therapies.